AC
MYGN icon

AXQ Capital’s Myriad Genetics MYGN Stock Holding History

AXQ Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Sell
37,122
-8,005
-18% -$36.3K 0.02% 709
2026
Q1 		$203K Buy
45,127
+29,436
+188% +$153K 0.03% 743
2025
Q4 		$96.5K Buy
15,691
+4,243
+37% +$30.8K 0.02% 657
2025
Q3 		$82.8K Buy
+11,448
New +$68K 0.03% 525

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AXQ Capital's MYGN Position: Q2 2026 in Review

AXQ Capital reduced its Myriad Genetics (MYGN) stake by 18% in Q2 2026, selling an estimated $36.3K and leaving 37,122 shares worth $212K. The position accounts for 0.02% of the portfolio, ranked #709.

AXQ Capital first reported a position in MYGN in Q3 2025 and has held it in 4 quarters since. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • AXQ Capital held 37,122 shares of Myriad Genetics worth $212K as of Q2 2026.
  • AXQ Capital sold 8,005 Myriad Genetics shares in Q2 2026, an estimated $36.3K.
  • Myriad Genetics made up 0.02% of AXQ Capital's portfolio in Q2 2026, its #709 holding.
  • AXQ Capital first reported a position in Myriad Genetics in Q3 2025 and has held it in 4 quarters since.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.